

**THE NINETH ANNUAL MEETING**

**2003**

**JAPAN SOCIETY OF  
GENE THERAPY**

**PROGRAM AND ABSTRACTS**

**Date**

July 18-20, 2003

**Venue**

The University of Tokyo  
Yayoi Auditorium Ichijo Hall

1-1-1, Yayoi, Bunkyo-ku  
Tokyo

# PROGRAM OF 9TH JSJT ANNUAL MEETING

( ):Chairperson

July 18, Friday		July 19, Saturday	
9:40-10:30	*MANAGERS' MEETING	9:30-12:10	<b>Gene Therapy Forum</b> (Asano S, Sasazuki T) <i>Richter King</i>
10:30-11:00	*DIRECTORS' MEETING	9:30-10:10 (F1)	<i>Dale Ando</i>
11:00-11:40	*COUNCILORS' MEETING	10:10-10:50 (F2)	<i>Noriyuki Kasahara</i>
12:00-12:50	<b>Opening Remarks &amp; General Assembly</b> <i>Shigetaka Asano</i>	10:50-11:30 (F3)	<i>Masaki Akiyama</i>
13:00-14:15	<b>Oral Session 1</b> <b>Cardiovascular Diseases</b> (Eto Y, Hamada H) Abstracts 1-5	11:30-12:00 (F4)	<i>Fabio Candotti</i>
14:15-15:15	<b>Gene Therapy of Aquired Disorders</b> (Kaneda Y, Endo F) Abstracts 6-9	12:00-12:40 (F5)	Lunch
15:20-17:25	<b>Educational Symposium</b> <b>(New Progress of Clone Thechnology and Stem Cell Research)</b> (Nakauchi K, Tani K) <i>Kiyoshi Ando</i>	12:40-13:50	<b>Oral Session 2</b> <b>Gene Therapy of Congenital Disorders</b> (Shimada T, Matsubara Y) Abstracts 10-15
15:20-15:45 (ES1)	<i>Takashi Shinohara</i>	13:50-15:20	<b>Cancer</b> (Hirai H, Sugimoto Y) Abstracts 16-21
15:45-16:10 (ES2)	<i>Hirofumi Suemori</i>	15:20-16:50	<b>Poster Session 1</b> (Abstracts 37-72)
16:10-16:35 (ES3)	<i>Hideki Taniguchi</i>	16:50-17:50	
16:35-17:00 (ES4)	<i>Atsuo Ogura</i>		
17:00-17:25 (ES5)			
18:00	<b>Reception</b> at Yayoi Auditorium		

( ):Chairpersons

**July 20, Sunday**

9:30-10:30	<b>Presidential Lecture</b> <b><i>Gene Therapy Trials in Prostate Cancer Patients</i></b> <b><i>Bernd Gaensbacher</i></b> (Matsuda I)
10:30-12:15	<b>Oral Session 3</b> <b><i>Stem Cells</i></b> (Ozawa K, Saijo N) <b><i>Abstracts 22-28</i></b>
12:15-13:30	Lunch
13:30-14:30	<b>Cell and Gene Targeting</b> (Ohashi T, Fujiwara T) Abstract 29-32
14:30-15:30	<b>Vector Development</b> (Saito I, Tahara H) Abstracts 33-36
15:30-16:30	<b>Poster Session 2</b> Abstracts 73-104  (Drinks will be provided) Beer, softdrinks, etc.
16:30	<b>Closing Remarks</b> <b><i>Shigetaka Asano</i></b>

## **Presidential Lecture**

Date: July 20, 2003

Time: 9:30-10:30

Chairperson: Ichiro Matsuda

**Bernd Gaensbacher** (*President of ESGT, Institut fuer Exp. Onkologie und Therapieforschung der Technischen Universitaet Muenchen, Germany*)

Gene Therapy Trials in Prostate Cancer Patients

## **Educational Symposium**

*New Progress of Clone Technology and Stem Cell Research*

Date: July 18, 2003

Time: 15:20-17:25

Chairpersons: Hiromitsu Nakauchi, Kenzaburo Tani

**Yukari Muguruma, Kiyoshi Ando**

Isolation and Maintenance of Multipotent Progenitor Cells

**Takashi Shinohara**

Establishment of Germline Stem (GS) Cells in Culture: A New Approach for Germline Manipulation

**Hirofumi Suemori**

Primate Embryonic Cell Lines

**Hideki Taniguchi**

Clonal Identification of Pluripotent Stem Cells in the Developing Liver and Pancreas using Flowcytometric Cell Sorting

**Atsuo Ogura**

Recent Advances in Somatic Cell Cloning for Laboratory Animals

## Gene Therapy Forum

Date: July 19, 2003

Time: 9:30-12:10

Chairpersons: Shigetaka Asano, Takehiko Sasazuki

**Richter King** (*VP research, GenVec Inc.*)

Applications of Adenovirus Vectors to Treat Cancer and Blindness

**Dale Ando** (*Cell Genesis, Inc*)

A Phase I/II Dose Escalation Trial of the Intraprostatic Injection of CG7870, a Prostate Specific Antigen-Dependent Oncolytic Adenovirus in Patients with Locally Recurrent Prostate Cancer Following Definitive Radiotherapy

**Noriyuki Kasahara** (*Department of Medicine, University of California Los Angeles*)

Tumor-Selectively Replicating Retrovirus Vectors Achieve Highly Efficient Intratumoral Therapeutic Gene Transfer and Long Term Survival Benefit *In Vivo*

**Masaki Akiyama** (*Fuso Pharmaceutical Industries, Ltd.*)

Development of a Genetically-Modified Adenovirus Vector that Specifically Targets Tumors via the Bloodstream Following Systemic Administration

**Fabio Candotti** (*Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health*)

Gene Therapy Trials for Adenosine Deaminase Deficiency

**PROGRAM**  
**Oral Session 1 (Abstracts 1-9)**

Day 1: July 18, 2003

*Cardiovascular Diseases 13:00 – 14:15*

Chairpersons: Yoshikatsu Eto, Hirofumi Hamada

1. **Clinical Results from TREAT-HGF (Japan Trial to Treat Peripheral Arterial Disease by Therapeutic Angiogenesis using Hepatocyte Growth Factor Gene Transfer)**

*Takeya Y., Morishita R., Aoki M., Makino H., Hashiya N., Yamasaki K., Junya A., Kaneda Y., Ogiwara T.*

2. **VEGF Gene Therapy on Acute Phase of Myocardial Infarction Induces Pulmonary Edema and Increases the Mortality in Rat Model**

*Ito Y., Takahashi K., Kobune M., Huang J., Dehari H., Uzuka T., Hamada H.*

3. **Adeno-Associated Viral Vector-Mediated Intramuscular Delivery of Interleukin-10 Gene Reduces Blood Pressure and Stroke Episode in Stroke-Prone Spontaneously Hypertensive Rats**

*Nomoto T., Okada T., Shimazaki K., Yoshioka T., Maeda Y., Takeuchi K., Mizukami H., Matsushita T., Kume A., Katsura K., Yamamoto K., Ikeda U., Ohkawara S., Katayama Y., Ozawa K.*

4. **Therapeutic Angiogenesis for Critical Limb Ischemia by Gene Transfer of Angiopoietin-1 Combined with VEGF**

*Morikawa M., Ito Y., Yamauchi A., Takahashi K., Huang J., Hamada H., Abe T.*

5. **Angiopoietin-1 Gene-Therapy for Acute Myocardial Infarction: Reduction of Infarct Size and Preservation of Cardiac Function in the Rat Model**

*Takahashi K., Ito Y., Morikawa M., Huang J., Kobune M., Tsukamoto M., Dehari H., Sasaki K., Nakamura K., Uchida H., Hirai S., Abe T., Hamada H.*

*Gene Therapy of Acquired Disorders 14:15 – 15:15*

Chairpersons: Yasufumi Kaneda, Fumio Endo

6. **Preclinical Safety Study (Acute Toxicity and Biodistribution) for Intramuscular Administration of F-Defective, Non-Transmissible Recombinant Sendai Virus Vector Expressing Human FGF-2 using Non-Human Primate**

*Yonemitsu Y., Terao K., Ono F., Kuwahara T., Akihiro I., Hara H., Iwasaki H., Hasegawa M., Sueishi K.*

7. **Restoration of L-Dopa Efficacy in a Primate Model of Parkinson's Disease by Adeno-Associated Virus Vector-Mediated Gene Delivery of Aromatic L-Aminoacid Decarboxylase**  
*Muramatsu S., Ikeguchi K., Fujimoto K., Nagata M., Nara Y., Tsuchida J., Kawasaki K., Ono F., Okada T., Mizukami H., Kume A., Nagatsu T., Terao K., Nakano I., Ozawa K.*
8. **Hepatocyte Growth Factor (HGF) Gene Transfer in Cerebrospinal Fluid Can Protect and Ameliorate Hearing Impairment in Rats**  
*Oshima K., Shimamura M., Mizuno S., Tamai K., Doi K., Morishita R., Nakamura T., Kubo T., Kaneda Y.*
9. **Comparison of the Ointment Containing NF- $\kappa$ B Decoy Oligodeoxynucleotides with Tacrolimus Hydrate: Rapid Regression and No Tachyphylaxis in the Treatment of Atopic Dermatitis in NC/Nga Atopic Mice Model**  
*Nakamura H., Aoki M., Tamai K., Oishi M., Ogihara T., Kaneda Y., Morishita R.*

## Oral Session 2 (Abstracts 10 – 21)

Day 2: July 19, 2003

*Gene Therapy of Congenital Disorders 13:50-15:20*

Chairpersons: Takashi Shimada, Yoichi Matsubara

10. **Correction of the CNS Pathology and Function of MPSVII Mice by Intraventricular Transplantation of Genetically Modified Bone Marrow Stromal Cells**  
*Sakurai K., Izuka S., Shen DS., Mori T., Umezawa A., Ohashi T., Eto Y.*
11. **Brain Transplantation of Genetically Engineered Human Neural Stem Cells Globally Corrects Brain Lesions in Mucopolysaccharidosis VII Mouse**  
*Meng XL., Shen JS., Ohashi T., Maeda H., Sly WS., Kim SU., Eto Y.*
12. **AAV Vector Mediated Gene Therapy of Fabry Disease: Histological and Functional Evaluation of Fabry Knockout Mice**  
*Hirai Y., Seino Y., Fukuda Y., Shimada T.*
13. **Serotypes of AAV Vectors: Muscle-Directed Expression of Human Coagulation Factor IX in Cynomolgus Monkeys**  
*Mizukami H., Mimuro J., Ogura T., Ono F., Kobayashi E., Muramatsu S., Madoiwa S., Matsushita T., Okada T., Hanazono Y., Kume A., Terao K., Sakata Y., Ozawa K.*
14. **Serotypes of AAV Vectors: Muscle-Directed Expression of Coagulation Factor IX in Mice**  
*Mizukami H., Mimuro J., Ogura T., Mochizuki S., Matsushita T., Okada T., Kume A., Muramatsu S., Madoiwa S.,*

*Sakata Y, Ozawa K.*

15. **Abnormal Proliferation of Hematopoietic Progenitors in Diamond-Blackfan Anemia (DBA) Patients with Ribosomal Protein S19 (RPS19) Mutation Are Partially Restored by Lentiviral Mediated Expression of RPS19**

*Hamaguchi I, Nishiura H, Flygare J, Brun ACM, Ooka A, Dahl N, Richter J, Karlsson S.*

*Cancer 15:20-16:50*

Chairpersons: Hisamaru Hirai, Yoshikazu Sugimoto

16. **Multicenter Phase I Trial of Adenovirus Expressing the Wild-type p53 Gene (Ad-p53) Administered Intratumorally for the Treatment of Advanced Lung Cancer Patients: Safety, Efficacy, Transgene Expression, and Shedding in Biological Fluids**

*Fujiwara T, Tanaka N, Kataoka M, Nakamura H, Saji H, Kato H, Saijo Y, Nukiwa T, Yoshimura K, Akiba T, Sato T, Eto Y.*

17. **Transcriptionally and Transductionally Targeted Conditionally Replicating Adenovirus for Gastrointestinal Cancers**

*Davydova J, Gavrikova T, Curiel DT, Yamamoto M.*

18. **Suppression of Ovarian Cancer by Muscle-Mediated Expression of Soluble VEGFR-1/Flt-1 using AAV Serotype 1-Derived Vector**

*Takei Y, Mizukami H, Saga Y, Kohno T, Matsushita T, Okada T, Hanazono Y, Kume A, Suzuki M, Ozawa K.*

19. **Enhancement of the Therapeutic Efficacy of an Oncolytic Herpes Simplex Virus (HSV) by Two Membrane-Fusion Mechanisms: Comparison with a Conventional HSV Therapy**

*Nakamori M, Fu X, Yamaue H, Zhang X.*

20. **Targeted Disruption of Tumor Vasculature with A Multi-Mutated, Conditionally Replication-Competent Herpes Simplex Type I Virus (HSV-1) Expressing the RS1 (Icp4) Gene under the Control of Smooth Muscle-Specific Human Calponin Promotor**

*Yamamura H, Takahashi K.*

21. **Immunogenicity and Protective Efficacy of Orally Administered Recombinant Lactococcus Lactis Expressing Surface-Bound HIV Env**

*Xin KQ, Okuda K.*



## Oral Session 3 (Abstracts 22 – 36)

Day 3: July 20, 2003

*Stem Cells 10:30-12:15*

Chairpersons: Keiyo Ozawa, Nagahiro Saijo

22. **Possible Myeloprotective Effect of the MDR1 Gene Therapy in the Post-Transplantation Chemotherapy Against Breast Cancer**  
*Sugimoto Y., Mitsuhashi J., Tsukahara S., Minowa S., Nagamine T., Shibata H., Ito Y., Tsuruo T., Hatake K., Takahashi S.*
23. **A Novel Method of Hematopoietic Stem Cell Gene Therapy without Conditioning: the Intra-Bone Marrow Transplantation with the Selective Amplifier Gene in Primates.**  
*Ueda K., Hanazono Y., Shibata H., Ageyama N., Nagashima T., Tabata T., Ueda Y., Kume A., Ikehara S., Hasegawa M., Terao K., Ozawa K.*
24. **A Genetic Tracking Approach to Studying *In Vivo* Hematopoiesis and Response to Cytokines in Non-Human Primates**  
*Kuramoto K., Sellers S., Agricola B., Metzger M., Donahue R., von Kalle C., Dunbar C.*
25. **Genetic Modification of Embryonic Stem Cells by the Methylation Resistance Retroviral Vector GCDNsap**  
*Hamanaka S., Usui J., Takahashi S., Nagata M., Kaneko S., Nagasawa T., Nakauchi H., Onodera M.*
26. **Engraftment and Teratoma Formation After Allogeneic in Utero Transplantation of Gene-Modified Primate Embryonic Stem Cells**  
*Hanazono Y., Asano T., Ageyama N., Takeuchi K., Momoeda M., Kitano K., Sasaki K., Ueda Y., Suzuki Y., Kondo Y., Torii R., Ookawara S., Hasegawa M., Terao K., Ozawa K.*
27. **Efficient and Stable Transduction of Cardiomyocytes Derived From Primate Embryonic Stem Cells with a Simian Immunodeficiency Viral Vector**  
*Nagata M., Takahashi M., Muramatsu S., Ueda Y., Hanazono Y., Takeuchi K., Okada K., Suzuki Y., Kondo Y., Suemori M., Ikeda U., Nakano I., Kobayashi E., Hasegawa M., Ozawa K., Nakatsuji N., Shimada K.*
28. **Genetic Manipulation of Common Marmoset (*Callithrix jacchus*) Embryonic Stem Cells using the Third Generation Lentiviral Vector**  
*Sasaki E., Nakagawa C., Hiroshima T., Nakazaki Y., Hanazawa K., Bai YS., Soda Y., Li XJ., Izawa K., Ishii H., Tanioka Y., Hamada H., Watanabe S., Asano S., Tani K.*

*Cell and Gene Targeting 13:30-14:30*

Chairpersons: Toya Ohashi, Toshiyoshi Fujiwara

29. **Reduced Natural Adenovirus (Ad) Transduction to Mouse Liver by Ad Vectors Containing CAR-Binding Ablated Ad Type 5 Fiber Knob, Ad Type 35 Fiber Shaft, and Ad Type Penton Base with the Deletion of RGD Motif**

*Koizumi N., Mizuguchi H., Sakurai F., Yamaguchi T., Watanabe Y., Hayakawa T.*

30. **Electroporation-Mediated Transfer of Short Interfering RNA (siRNA) Induces Specific Gene Knockdown in Murine Skeletal Muscle *In Vivo***

*Kishida T., Asada H., Gojo S., Ohashi S., Shin-ya M., Yasutomi K., Terauchi R., Kubo T., Imanishi J., Mazda O.*

31. **An Attempt to Apply Small Interfering RNA to Cancer Gene Therapy Through Use of Tumor-Targeting Peptide Vector**

*Aoki Y., Otsuki T., Miyamoto T., Hashizume K.*

32. **Development of An Efficient Small Interfering RNA (siRNA) Expression System with a Lentiviral Vector and Its Application to Cancer Gene Therapy**

*Sumitomo H., Miyagishi M., Miyoshi H., Taira K., Kawakami Y.*

*Vector Development 14:30-15:30*

Chairpersons: Izumu Saito, Hideaki Tahara

33. **Modification of Transcription and Replication Caused Further Attenuation of Gene(s)-Deleted Sendai Virus Vectors**

*Inoue M., Tokusumi Y., Ban H., Kato A., Nagai Y., Iida A., Hasegawa M.*

34. **The Improvement in Pseudotyping of Lentiviral Vectors using Fusion (F) and Hemagglutinin-Neuraminidase (HN) Glycoproteins from Sendai Virus (SeV)**

*Mitomo K., Shirohzu H., Hashimoto T., Izumi H., Tabata T., Ueda Y., Alton EFWF., Hasegawa M.*

35. **Pathways of Removal of Free DNA Vector Ends in Mouse Hepatocytes Transduced with rAAV Vectors**

*Nakai H., Storm TA., Fuess S., Kay MA.*

36. **A Lentivirus/Adenovirus Hybrid Vector for Efficient and Stable Gene Transfer via a Two-Stage Mechanism**

*Kubo S., Mitani K.*

## Poster Session (1)

Day 2: July 19, 2003 (16:40 – 17:40)

### *Cardiovascular Diseases*

37. **Adenoviral Overexpression of Angiopoietin-1 Accelerates Early Recovery of Blood Perfusion and Inhibits Limb Necrosis in the Mice Model of Acute Hindlimb Ischemia**  
*Ikeda K., Ito Y., Morikawa M., Huang J., Takahashi K., Kobune M., Abe T., Hamada H.*
38. **Cardiac Protection by Adenoviral Bcl-xL Gene Transfer from Ischemia and Reperfusion Injury in the Rat Heart**  
*Huang J., Ito Y., Uchida H., Kobune M., Nakamura K., Dehari H., Takahashi K., Morikawa M., Hamada H.*
39. **Efficacy of Therapeutic Angiogenesis by Transfection of Hepatocyte Growth Factor Gene using Left Ventricular Electromechanical Mapping (Porcine Myocardial Infarction Model)**  
*Azuma J., Aoki M., Yamasaki K., Kaneda Y., Ogihara T., Morisita R.*
40. **Inhibitory Effect of Chimera Decoy Oligodeoxynucleotides (ODN) Against Ets and NF $\kappa$ B on the Progression of Abdominal Aortic Aneurysms (AAA)**  
*Miyake T., Aoki M., Morishita R.*
41. **Transplantation and *In Vivo* Follow-Up of Lentivirally Transduced CD34<sup>+</sup> Cells in a Nonhuman Primate Myocardial Infarction Model**  
*Yoshioka T., Ageyama N., Shibata H., Yasu T., Ueda K., Takeuchi K., Matsui K., Yamamoto K., Tabata T., Ueda Y., Hasegawa M., Ookawara S., Terao K., Shimada K., Ikeda U., Ozawa K., Hanazono Y.*
42. **Involvement of VEGF-C/Flt-4 System in Therapeutic Angiogenesis of FGF-2 Gene Transfer in Murine Ischemic Hind Limbs**  
*Onimaru M., Yonemitsu Y., Tanii M., Tsutsumi N., Nakagawa K., Nakashima Y., Hasegawa M., Sueishi K.*
43. **Platelet-Derived Growth Factor Receptor-Alpha Signaling Is Required for Therapeutic Angiogenesis Induced by Fibroblast Growth Factor-2**  
*Tsutsumi N., Yonemitsu Y., Onimaru M., Tanii M., Maehara Y., Hasegawa M., Sueishi K.*
44. **Myocardial Injection of Naked CA Promoter-Based Plasmid Mediates Efficient Transgene Expression in Rat Heart**  
*Huang J., Ito Y., Sasaki K., Kobune M., Takahashi K., Dehari H., Nakamura K., Uchida H., Hamada H.*

### *Gene Therapy of Acquired Disorders*

45. **AAV Vector Mediated Anti-Angiogenic Gene Therapy for Collagen-Induced Arthritis in Mice**  
*Takahashi H., Miyake K., Yoshino S., Shimada T.*
46. **Isolated Langerhans Island from Diabetic Mice Induced by High Fat Diet: Gene Therapy for**

## **Telomere Loss and Mutated Mitochondrial DNA**

*Sone H., Yanagisawa Y., Kagawa Y., Endo H.*

47. **Hepatocyte Growth Factor Gene Transfer into the Liver via the Portal Vein using Electroporation Attenuates the Rat Liver Cirrhosis**

*Matsuno Y., Iwata H., Umeda Y., Takagi H., Mori Y., Hirose H.*

48. **Combination Gene Therapy of AdHGF and AdT ! TR for Rat Liver Cirrhosis after Partial Hepatectomy**

*Ozawa S., Uchiyama K., Iwahashi M., Nakamori M., Ueda K., Yamaue H.*

49. **Adenovirus-Mediated Gene Transfer of Interferon  $\alpha$  Improves Dimethylnitrosamine-Induced Liver Cirrhosis in Rat Model**

*Suzuki K., Aoki K., Ohnami S., Yoshida K., Kazui T., Kato N., Inoue K., Kohara M., Yoshida T.*

50. **Long-Term Reversal of Hypercholesterolemia using a Helper-Dependent Adenovirus Expressing Low-Density Lipoprotein Receptor in a Mouse Model of Familial Hypercholesterolemia**

*Nomura S., Oka K., Chan L.*

51. **Electroporation-Mediated Short Interfering RNAs Transfer Targeting Glomeruli**

*Takabatake Y., Isaka Y., Mizui M., Kawachi H., Shimizu F., Ito T., Imai E., Hori M.*

52. **Simian Lentiviral Vector-Mediated Retinal Gene Transfer of Pigment Epithelium-Derived Factor Protects Retinal Degeneration and Electrical Defect in Royal College of Surgeons Rats**

*Miyazaki m., Ikeda Y., Yonemitsu Y., Goto Y., Sakamoto T., Tabata T., Ueda Y., Hasegawa M., Tobimatsu S., Ishibashi T., Sueishi K.*

53. **Gene Therapy by Naked Human HGF Plasmid Transfer to Parkinson's Disease**

*Koike H., Tomita N., Shimamura M., Ogihara T., Kaneda Y., Morishita R.*

54. **Tissue Degeneration by the Decrease of HCNP-Pp Expression by Adenoviral Vector System in the Adult Rat Hippocampus**

*Matsukawa N., Fujimori O., Katoh H., Nakazawa H., Maki M., Hattori M., Morishita M., Ojika K.*

## *Gene Therapy of Congenital Disorders*

55. **Hemophilia A Gene Therapy using Adeno-Associated Virus Dual Vector System**

*Matsushita T., Mimuro J., Madoiwa S., Mizukami H., Urabe M., Okada T., Hanazono Y., Kume A., Sakata Y., Ozawa K.*

56. **Expansion of Respiratory Burst-Positive Granulocytes in Chronic Granulomatous Disease Mice with a Second Generation Selective Amplifier Gene**

*Kume A., Hara T., Hanazono Y., Mizutani H., Okada T., Tsurumi H., Moriwaki H., Nagashima T., Ueda Y.,*

*Hasegawa M., Ozawa K.*

57. **An AAV Vector-Mediated Micro-Dystrophin Expression Ameliorates Dystrophic Phenotypes of MDX Muscles**

*Sakamoto M., Yoshimura M., Yuasa K., Ikemoto M., Takeda S.*

58. **Molecular Mechanism of Over-Expression of Endogenous Utrophin in AxCALacZ-Injected Neonatal MDX Skeletal Muscles**

*Itoh Y., Takahashi J., Fujimori K., Miyagoe-Suzuki Y., Takeda S.*

59. **Successful Gene Transfer of Neural Progenitor Cells by Intra-Ventricular Administration of Recombinant Adenovirus in Utero: Implication for CNS Gene Therapy of Lysosomal Storage Disease**

*Shen JS., Meng XL., Ohashi T., Maeda H., Eto Y.*

60. **Hemagglutinating Virus of Japan (HVJ) Envelope Vector Successfully Mediated Beta-Glucuronidase Gene into Mucopolysaccharidosis VII Mice**

*Fukuhara Y., Hara Y., Okuyama T., Kato M., Li XK*

#### *Cancer*

61. **Targeted Gene Therapy for Epstein-Barr Virus Positive Hematological Malignancies**

*Ando J., Tamayose K., Kashiwakura Y., Sugimoto K., Oshimi K.*

62. **Suppression of Granulocytosis and Thrombocytosis by Systemic Anti-Angiogenic Gene Therapy in P230 bcr/abl Induced Myeloproliferative Disorders**

*Inokuchi K., Miyake K., Miyake NS, Dan K., Shimada K.*

63. **Lentivirus-Mediated Gene Transfer for Combination Anti-Angiogenic Therapy of Solid Tumors**

*Sazawa A., Shichinohe T., Mizutani K., Harabayashi T., Shinohara N., Kasahara N., Nonomura K.*

64. **Suicide Gene Therapy for Human Gallbladder Cancer using an E1B-55kD Deficient Restricted Replication-Competent Adenoviral Vector Carrying Uracil Phosphoribosyltransferase (UPRT) Gene**

*Seo E., Abei M., Fukuda K., Wakayama M., Ugai H., Murata T., Tanaka N., Hamada H., Yokoyama K.*

65. **Adenovirus-Mediated HGF/NK4 Gene Therapy for Peritoneal Dissemination of Gastric Carcinoma**

*Ueda K., Iwahashi M., Nakamura M., Nakamori M., Matsuura I., Ojima T., Matsumoto K., Nakamura T., Yamaue H.*

66. **AAV-Mediated Continuous Secretion of Endostatin Inhibits Pancreatic Tumor Growth and Metastasis: Influence of Route of AAV Vector Administration**

Noro T., Miyake K., Suzuki N., Uchida E., Misawa T., Yamazaki Y., Shimada T.

67. **Electrochemo-Gene-Therapy As a Novel Therapeutic Intervention against Metastatic Malignancies**

Kishida T., Asada H., Itokawa Y., Yasutomi K., Shinya M., Gojo S., Cui FD., Ueda Y., Yamagishi H., Imanishi J., Mazda O.

*Oncolytic Virus*

68. **A Conditional Replication-Competent Adenoviral Vector, Ad-COX2-E1A, to Target the COX-2 Expressing Human Bladder Cancer Cells**

Shirakawa T., Zhang Z., Kamidono S., Hamada K., Gotoh A.

69. **Combined Use of E1 Double-Restricted Oncolytic Adenovirus Augments the Efficacy of Tumor-Specific Suicide Gene Therapy Approach**

Fukuda K., Abei M., Seo E., Wakayama M., Ugai H., Murata T., Tanaka N., Hamada H., Yokoyama KK.

70. **Infectivity and Efficacy of Restricted Replication Competent Adenovirus for Biliary Cancer and Its Improvement by RGD-Fiber Modified Adenovirus**

Wakayama M., Abei M., Fukuda K., Seo E., Ugai H., Murata T., Tanaka N., Hamada H., Yokoyama K.

71. **Preclinical Safety Evaluation and Biodistribution of a Novel Ribonucleotide Reductase-Defective and Ganciclovir/Aciclovir-Sensitive Oncolytic Herpes Simplex Type I Virus (HSV-1) D12.Calp " Rr Designed to Target Human Leiomyosarcoma, Gastrointestinal Stromal Tumors, Malignant Fibrous Histiocytoma and Myoma**

Takahashi K., Yamamura H.

72. **Improvement of Oncolytic M Gene-deficient Sendai Virus Vectors: Enhanced Fusogenicity of Human Tumor Cells Expressing Matrix Metalloproteinases**

Kinoh H., Inoue M., Washizawa K., Yamamoto T., Matsuo M., Fujikawa S., Iida A., Nagai Y., Hasegawa M.

**Poster Session (2)**

Day 3: July 20, 2003 (15:30 – 16:30)

*Immune Gene Therapy*

73. **Transfer of NF $\kappa$ B Decoy using Ultrasound-Mediated Gene Transfer Prolonged Survival of Rat Renal Allografts**

Tomita N., Azuma H., Koike H., Katsuoka Y., Ogihara T.

74. **Anti-Tumor Effect by a CC Chemokine, CCL27, Introduces into Tumor Cells Through a Recombination Adenovirus Vector**

Gao JQ., Tsuda Y., Katayama K., Nakayama T., Hatanaka Y., Tani Y., Mizuguchi H., Hayakawa T., Yoshie O., Tsutsumi Y., Mayumi T., Nakagawa S.

75. **Expression of the Interleukin-23 Gene in Tumor Cells Produced T Cell-Dependent Antitumor Effects and Induced Systemic Immunity in the Inoculated Host Animals**

Tagawa M., Sakiyama S.

76. **Gene Transfer of CX3C Chemokine Suppresses Tumor Growth *In Vivo***

Xin H., Kikuchi T., Andarini S., Ohkouchi S., Suzuki T., Pladono P., Honjo T., Nukiwa T., Saijo Y.

77. **Combination of Interferon-Beta Gene Therapy with Dendritic-Cell Based Cell Therapy Augments Antitumor Effect on Intracranial Malignant Gliomas**

Nakahara N., Mizuno M., Wakabayashi T., Okada H., Yoshida J.

78. **The Role of Chemokines Increased by Gene Expression Analysis in Antitumor Effect of Antitumor Murine Model using Tumor Cells Transduced with GM-CSF Gene**

Beppu Y., Hase H., Nakazaki Y., Asano S., Tani K.

79. **Adenovirus Mediated B7-1 Gene Transfection Inhibits Lymph Node Metastasis by Human Gastric Cancer Cells**

Kosaka K., Yashiro M., Tanaka H., Hirakawa K.

#### *Stem Cells*

80. **Efficient Gene Delivery and Stable Transgene Expression in Primate Embryonic Stem Cells by the Non-Integrating Sendai Virus Vector**

Sasaki K., Ueda Y., Inoue M., Asano T., Harii K., Hasegawa M., Ozawa K., Hanazono Y.

81. **Recombinant Sendai Virus Provides a Highly Efficient Gene Transfer into Human Cord Blood-Derived Hematopoietic Stem Cells**

Kusuhara K., Jin CH., Yonemitsu Y., Nomura A., Okano S., Hasegawa M., Sueishi K., Hara T.

82. **Construction of the Hematopoietic Lineage Specific Gene Expression System with an HIV-1 Derived Self-Inactivating Lentivirus Vector**

Yasui K., Furuta R., Tani Y., Fujisawa J.

#### *Cell and Gene Targeting*

83. **Somatic Gene Targeting with RNA/DNA Chimeric Oligonucleotides: An Analysis with a Highly Sensitive Reporter Mouse System**

Ino A., Yamamoto S., Kaneda Y., Kobayashi I.

84. **Maxzymes and Small Hairpin-Type RNAs That Are Driven by a tRNA Promoter Specifically**

**Cleave A Chimeric Gene Associated with Leukemia *In Vitro* and *In Vivo***

*Oshima K., Kawasaki H., Soda Y., Tani K., Tojo A., Asano S., Taira K.*

85. **Efficient and Specific Cytotoxicity of Anti-CD19 Antibody-Binding Liposomes Containing Imatinib to Ph<sup>+</sup> ALL Cells**

*Harata M., Soda Y., Ooi J., Takizawa T., Chen M., Bai Y., Izawa K., Kobayashi S., Ohno N., Tomonari A., Nagamura F., Takahashi S., Uchimaru K., Iseki T., Sugita K., Nakazawa S., Tojo A., Maruyama K., Tani K., Asano S.*

86. **Antisense Therapy Targeting Antiapoptotic Protein, Bcl-2 for Enhancement of Chemotherapeutic Effect in Solid Tumors**

*Kim R., Emi M., Tanabe K., Toge T.*

87. **Atelocollagen-Mediated Effective Transfer of Small Interfering RNAs in Mammalian Cells**

*Minakuchi Y., Kosaka N., Sasaki H., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Terada M., Ochiya T.*

*Vector Development*

88. **Improved Tetracycline-Inducible Regulation System by a Single Self-Containing Adenovirus Vector**

*Xu ZL., Mizuguchi H., Sakurai F., Yamaguchi T., Mayumi T., Hayakawa T.*

89. **Characterization of *In Vivo* Gene Transfer Property of an Adenovirus Serotype 35 Vector**

*Sakurai F., Mizuguchi H., Yamaguchi T., Hayakawa T.*

90. **A Simple and Efficient Method for Constructing An Adenoviral cDNA Expression Library**

*Hatanaka K., Ohnami S., Yoshida K., Miura Y., Aoyagi K., Sasaki H., Asaka M., Terada M., Yoshida T., Aoki K.*

91. **Mutations of Infective Fiber-Modified Recombinant Adenoviruses Generated by Multiple Passages**

*Ugai H., Inabe K., Hirose M., Kujime Y., Murata T., Hamada H., Yokoyama KK.*

92. **Detection of Replication-Competent Adenoviruses Spiked in Recombinant Adenovirus Vector Products by Infectivity-PCR Combined with Glass Beads-Based DNA Extraction**

*Ishii-Watanabe A., Uchida E., Iwata A., Satoh K., Fan K., Murata M., Mizuguchi H., Kawasaki N., Kawanishi T., Yamaguchi T., Hayakawa T.*

93. **Variance of Infectious Titer and Particle Concentration Measured in the Stability Test of Adenovirus Vector, AdGVCD.10**

*Yamada O., Yoshida H., Akiyama M., Shimamura H., Matsushita Y., Iwai T., Zhang Z., Araki H.*

94. **AAV Serotype 2 Vectors Preferentially Integrate into Active Genes in Mice**



*Nakai H., Montini E., Fuess S., Storm TA., Grompe M., Kay MA.*

95. **Systemic Administration of Recombinant AAV-2 Vectors in Cynomolgus Monkeys: Organ-Tropism and Expression of Transgene**

*Mori S., Takeuchi T., Enomoto Y., Ono F., Sata T., Kanda T.*

96. **c-Met Is a Co-Receptor for Adeno-Associated Virus Type 2 (AAV 2) Infection**

*Kashiwakura Y., Tamayose K., Nakamura T., Shimada T., Daida H.*

97. **The Histone Deacetylase Inhibitor Enhances Recombinant Adeno-Associated Virus-Mediated Gene Transfer into Cancer Cells**

*Okada T., Nomoto T., Shimazaki K., Iwata-Okada M., Yoshioka T., Ajalli R., Liu Y., Takahashi M., Matsushita T., Urabe M., Mizukami H., Kume A., Ozawa K.*

98. **Application of Newly Designed Sendai Virus Vector Deficient in both of Matrix and Fusion Genes for the Treatment of Brain Ischemia in Gerbils**

*Shirakura M., Inoue M., Fujikawa S., Washizawa K., Kanaya T., Tokusumi Y., Iida A., Yoshikawa Y., Hasegawa M.*

99. ***In Vitro* and *In Vivo* Comparative Studies of F-Defective and F, Hn-Defective Sev RNA Vectors**

*Kitazato K., Hara H., Shu T., Iida A., Ueda Y., Hasegawa M.*

100. **Recombinant Sendai Virus Vectors for Activated T-Lymphocytes**

*Okano S., Yonemitsu Y., Hasegawa M., Sueishi K.*

101. **Enhancement of Ultrasound-Mediated Transfection by the Combination of Cavitation Facilitation and Plasma Membrane Modification**

*Ogawa R., Nozaki T., Kagiya G., Feril L., Fuse H., Kondo T.*

102. **An Essential Role of the His-8 Residue of the SDF-1  $\alpha$ -Chimeric, Tropism-Redirected Env Protein of the Moloney Murine Leukemia Virus in the Regulation of the Post-Receptor Binding Events**

*Katane M., Fujita R., Takao E., Kubo Y., Amanuma H.*

103. **Inhibitory and Enhancing Effects of Insertion of Central Polypurine Tract and Central Termination Sequence on Gene Expression with Vectors Derived from Human Immunodeficiency Virus Type 1**

*Sakuma R., Kitamura Y.*

104. **Expansion of Gene-modified Hematopoietic Cells by Second Generation Selective Amplifier Genes (SAGs) in the Secondary Transplanted Mice**

*Ueda Y., Nagashima T., Hanazono Y., Ageyama N., Kume A., Terao K., Ozawa K., Hasegawa M.*

## Author Index

Abe T.	4, 5, 37	Daida H.	96	Grompe M.	94
Abei M.	64, 69, 70	Dan K.	62	Hamada H.	2, 4, 5, 28, 37, 38
Ageyama N.	23, 26, 41, 104	Davydova J.	17		44, 64, 69, 70, 91
Agricola B.	24	Dehari H.	2, 5, 38, 44	Hamada K.	68
Ajalli R.	97	Doi K.	8	Hamaguchi I.	15
Akiba T.	16	Donahue R.	24	Hamanaka S.	25
Akihiro I.	6	Dunbar C.	24	Hanai K.	87
Akiyama M.	93	Emi M.	86	Hanazawa K.	28
Alton EFWF.	34	Endo H.	46	Hanazono Y.	13, 18, 23, 26, 27, 41
Amanuma H.	102	Enomoto Y.	95		55, 56, 80, 104
Andarini S.	76	Eto Y.	10, 11, 16, 59	Hara H.	6, 99
Ando J.	61	Fan K.	92	Hara T.	56, 81
Aoki K.	49, 90	Feril L.	101	Hara Y.	60
Aoki M.	1, 9, 39, 40	Flygare J.	15	Harabayashi T.	63
Aoki Y.	31	Fu X.	19	Harata M.	85
Aoyagi K.	90	Fuess S.	35, 94	Harii K.	80
Araki H.	93	Fujikawa S.	72, 98	Hase H.	78
Asada H.	30, 67	Fujimori K.	58	Hasegawa M.	6, 23, 26, 27, 33, 34
Asaka M.	90	Fujimori O.	54		41, 42, 43, 52, 56, 72
Asano S.	28, 78, 84, 85	Fujimoto K.	7		80, 81, 98, 99, 100, 104
Asano T.	26, 80	Fujisawa J.	82	Hashimoto T.	34
Azuma H.	73	Fujita R.	102	Hashiya N.	1
Azuma J.	39	Fujiwara T.	16	Hashizume K.	31
Bai Y.	85	Fukuda K.	64, 69, 70	Hatake K.	22
Bai YS.	28	Fukuda Y.	12	Hatanaka K.	90
Ban H.	33	Fukuhara Y.	60	Hatanaka Y.	74
Beppu Y.	78	Furuta R.	82	Hattori M.	54
Brun ACM.	15	Fuse H.	101	Hayakawa T.	29, 74, 88, 89, 92
Chan L.	50	Gao JQ.	74	Hirai S.	5
Chen M.	85	Gavrikova T.	17	Hirai Y.	12
Cui FD.	67	Gojo S.	30, 67	Hirakawa K.	79
Curiel DT.	17	Goto Y.	52	Hirose H.	47
Dahl N.	15	Gotoh A.	68	Hirose M.	91

## Author Index

Hiroyama T.	28	Iwata-Okada M.	97	Kawasaki N.	92
Honjo T.	76	Izawa K.	28, 85	Kay MA.	35, 94
Honma K.	87	Izuka S.	10	Kazui T.	49
Hori M.	51	Izumi H.	34	Kikuchi T.	76
Huang J.	2, 4, 5, 37, 38, 44	Jin CH.	81	Kim R.	86
Iida A.	33, 72, 98, 99	Junya A.	1	Kim SU.	11
Ikeda K.	37	Kagawa Y.	46	Kinoh H.	72
Ikeda U.	3, 27, 41	Kagiya G.	101	Kishida T.	30, 67
Ikeda Y.	52	Kamidono S.	68	Kitamura Y.	103
Ikeguchi K.	7	Kanaya T.	98	Kitano K.	26
Ikehara S.	23	Kanda T.	95	Kitazato K.	99
Ikemoto M.	57	Kaneda Y.	1, 9, 39, 53, 83	Kobayashi E.	13, 27
Imai E.	51	KanedaY.	8	Kobayashi I.	83
Imanishi J.	30, 67	Kaneko S.	25	Kobayashi S.	85
Inabe K.	91	Karlsson S.	15	Kobune M.	2, 5, 37, 38, 44
Ino A.	83	Kasahara N.	63	Kohara M.	49
Inokuchi K.	62	Kashiwakura Y.	61, 96	Kohno T.	18
Inoue K.	49	Katane M.	102	Koike H.	53, 73
Inoue M.	33, 72, 80, 98	Kataoka M.	16	Koizumi N.	29
Isaka Y.	51	Katayama K.	74	Kondo T.	101
Iseki T.	85	Katayama Y.	3	Kondo Y.	26, 27
Ishibashi T.	52	Kato A.	33	Kosaka K.	79
Ishii H.	28	Kato H.	16	Kosaka N.	87
Ishii-Watanabe A.	92	Kato M.	60	Kouno M.	87
Ito T.	51	Kato N.	49	Kubo S.	36
Ito Y.	2, 4, 5, 22, 37, 38, 44	Katoh H.	54	Kubo T.	8, 30
Itoh Y.	58	Katsuoka Y.	73	Kubo Y.	102
Itokawa Y.	67	Katsura K.	3	Kujime Y.	91
Iwahashi M.	48, 65	Kawachi H.	51	Kume A.	3, 7, 13, 14, 18, 23 55, 56, 97, 104
Iwai T.	93	Kawakami Y.	32	Kuramoto K.	24
Iwasaki H.	6	Kawanishi T.	92	Kusuhara K.	81
Iwata A.	92	Kawasaki H.	84	Kuwahara T.	6
Iwata H.	47	Kawasaki K.	7		

## Author Index

Li XJ.	28	Miyake NS, 62		Nagatsu T.	7
Li XK, 60		Miyake T.	40	Nakagawa C.	28
Liu Y.	97	Miyamoto T.	31	Nakagawa K.	42
Madoiwa S.	13, 14, 55	Miyazaki m.	52	Nakagawa S.	74
Maeda H.	11, 59	Miyoshi H.	32	Nakahara N.	77
Maeda Y.	3	Mizuguchi H.	29, 74, 88, 89, 92	Nakai H.	35, 94
Maehara Y.	43	Mizui M.	51	Nakamori M.	19, 48, 65
Maki M.	54	Mizukami H.	3, 7, 13, 14, 18, 55, 97	Nakamura H.	9, 16
Makino H.	1	Mizuno M.	77	Nakamura K.	5, 38, 44
Maruyama K.	85	Mizuno S.	8	Nakamura M.	65
Matsui K.	41	Mizutani H.	56	Nakamura T.	8, 65, 96
Matsukawa N.	54	Mizutani K.	63	Nakano I.	7, 27
Matsumoto K.	65	Mochizuki S.	14	Nakashima Y.	42
Matsuno Y.	47	Momoeda M.	26	Nakatsuji N.	27
Matsuo M.	72	Montini E.	94	Nakauchi H.	25
Matsushita T.	3, 13, 14, 18, 55, 97	Mori S.	95	Nakayama T.	74
Matsushita Y.	93	Mori T.	10	Nakazaki Y.	28, 78
Matsuura I.	65	Mori Y.	47	Nakazawa H.	54
Mayumi T.	74, 88	Morikawa M.	4, 5, 37, 38	Nakazawa S.	85
Mazda O.	30, 67	Morishita M.	54	Nara Y.	7
Meng XL.	11, 59	Morishita R.	1, 8, 9, 40, 53	Nishiura H.	15
Metzger M.	24	Morisita R.	39	Nomoto T.	3, 97
Mimuro J.	13, 14, 55	Moriwaki H.	56	Nomura A.	81
Minakuchi Y.	87	Muramatsu S.	7, 13, 14, 27	Nomura S.	50
Minowa S.	22	Murata M.	92	Nonomura K.	63
Misawa T.	66	Murata T.	64, 69, 70, 91	Noro T.	66
Mitani K.	36	Nagahara S.	87	Nozaki T.	101
Mitomo K.	34	Nagai Y.	33, 72	Nukiwa T.	16, 76
Mitsubishi J.	22	Nagamine T.	22	Ochiya T.	87
Miura Y.	90	Nagamura F.	85	Ogawa R.	101
Miyagishi M.	32	Nagasawa T.	25	Ogihara T.	1, 9, 39, 53, 73
Miyagoe-Suzuki Y.	58	Nagashima T.	23, 56, 104	Ogura T.	13, 14
Miyake K.	45, 62, 66	Nagata M.	7, 25, 27	Ohashi S.	30

## Author Index

Ohashi T.	10, 11, 59	Sakamoto T.	52	Shirohzu H.	34
Ohkawara S.	3	Sakata Y.	13, 14, 55	Shu T.	99
Ohkouchi S.	76	Sakiyama S.	75	Sly WS, 11	
Ohnami S.	49, 90	Sakuma R.	103	Soda Y.	28, 84, 85
Ohno N.	85	Sakurai F.	29, 88, 89	Sone H.	46
Oishi M.	9	Sakurai K.	10	Storm TA.	35, 94
Ojika K.	54	Sano A.	87	Sueishi K.	6, 42, 43, 52, 81, 100
Ojima T.	65	Sasaki E.	28	Suemori M.	27
Oka K.	50	Sasaki H.	87, 90	Sugimoto K.	61
Okada H.	77	Sasaki K.	5, 26, 44, 80	Sugimoto Y.	22
Okada K.	27	Sata T.	95	Sugita K.	85
Okada T.	3, 7, 13, 14, 18, 55, 56, 97	Sato T.	16	Sumitomo H.	32
Okano S.	81, 100	Satoh K.	92	Suzuki K.	49
Okuda K.	21	Sazawa A.	63	Suzuki M.	18
Okuyama T.	60	Seino Y.	12	Suzuki N.	66
Onimaru M.	42, 43	Sellers S.	24	Suzuki T.	76
Ono F.	6, 7, 13, 95	Seo E, 64		Suzuki Y.	26, 27
Onodera M.	25	Seo E.	69, 70	Tabata T.	23, 34, 41, 52
Ooi J.	85	Shen DS.	10	Tagawa M.	75
Ooka A.	15	Shen JS.	11, 59	Taira K.	32, 84
Ookawara S.	26, 41	Shibata H.	22, 23, 41	Takabatake Y.	51
Oshima K.	8, 84	Shichinohe T.	63	Takagi H.	47
Oshimi K.	61	Shimada K.	27, 41, 62	Takahashi H.	45
Otsuki T.	31	Shimada T.	12, 45, 66, 96	Takahashi J.	58
Ozawa K.	3, 7, 13, 14, 18, 23	Shimamura H.	93	Takahashi K.2, 4, 5, 20, 37, 38, 44, 71	
	26, 27, 41, 55, 56, 80, 97, 104	Shimamura M.	8, 53	Takahashi M.	27, 97
Ozawa S.	48	Shimazaki K.	3, 97	Takahashi S.	22, 25, 85
Pladono P.	76	Shimizu F.	51	Takao E.	102
Richter J.	15	Shin-ya M.	30	Takeda S.	57, 58
Saga Y.	18	Shinohara N.	63	Takei Y.	18
Saijo Y.	16, 76	Shinya M.	67	Takeuchi K.	3, 26, 27, 41
Saji H.	16	Shirakawa T.	68	Takeuchi T.	95
Sakamoto M.	57	Shirakura M.	98	Takeya Y.	1

## Author Index

Takizawa T.	85	Tsutsumi Y.	74	Yamamoto S.	83
Tamai K.	8, 9	Uchida E.	66, 92	Yamamoto T.	72
Tamayose K.	61, 96	Uchida H.	5, 38, 44	Yamamura H.	20, 71
Tanabe K.	86	Uchimaru K.	85	Yamasaki K.	1, 39
Tanaka H.	79	Uchiyama K.	48	Yamauchi A.	4
Tanaka N.	16, 64, 69, 70	Ueda K.	23, 41, 48, 65	Yamaue H.	19, 48, 65
Tani K.	28, 78, 84, 85	Ueda Y.	23, 26, 27, 34, 41, 52	Yamazaki Y.	66
Tani Y.	74, 82		56, 67, 80, 99, 104	Yanagisawa Y.	46
Tanii M.	42, 43	Ugai H.	64, 69, 70, 91	Yashiro M.	79
Tanioka Y.	28	Umeda Y.	47	Yasu T.	41
Terada M.	87, 90	Umezawa A.	10	Yasui K.	82
Terao K.	6, 7, 13, 23, 26, 41, 104	Urabe M.	55, 97	Yasutomi K.	30, 67
Terauchi R.	30	Usui J.	25	Yokoyama K.	64, 70
Tobimatsu S.	52	Uzuka T.	2	Yokoyama KK.	69, 91
Toge T.	86	von Kalle C.	24	Yonemitsu Y.	6, 42, 43, 52, 81, 100
Tojo A.	84, 85	Wakabayashi T.	77	Yoshida H.	93
Tokusumi Y.	33, 98	Wakayama M.	64, 69, 70	Yoshida J.	77
Tomita N.	53, 73	Washizawa K.	72, 98	Yoshida K.	49, 90
Tomonari A.	85	Watanabe S.	28	Yoshida T.	49, 90
Torii R.	26	Watanabe Y.	29	Yoshie O.	74
Tsuchida J.	7	Xin H.	76	Yoshikawa Y.	98
Tsuda Y.	74	Xin KQ.	21	Yoshimura K.	16
Tsukahara S.	22	Xu ZL.	88	Yoshimura M.	57
Tsukamoto M.	5	Yamada O.	93	Yoshino S.	45
Tsurumi H.	56	Yamagishi H.	67	Yoshioka T.	3, 41, 97
Tsuruo T.	22	Yamaguchi T.	29, 88, 89, 92	Yuasa K.	57
Tsutsumi N.	43	Yamamoto K.	3, 41	Zhang X.	19
Tsutsumi N..	42	Yamamoto M.	17	Zhang Z.	68, 93